Association of hypometabolism and amyloid levels in aging, normal subjects

Neurology

Volumn 82, Issue 22, 2014, Pages 1959-1967

  Lowe, Val J ^a   Weigand, Stephen D ^a   Senjem, Matthew L ^a   Vemuri, Prashanthi ^a   Jordan, Lennon ^a   Kantarci, Kejal ^a   Boeve, Bradley ^a   Jack Jr , Clifford R ^a   Knopman, David ^a   Petersen, Ronald C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; APOLIPOPROTEIN E4; FLUORODEOXYGLUCOSE F 18; PITTSBURGH COMPOUND B;

AGED; AGING; ALZHEIMER DISEASE; ANGULAR GYRUS; ARTICLE; BRAIN METABOLISM; BRAIN REGION; COGNITION; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HETEROZYGOTE; HUMAN; HUMAN EXPERIMENT; HYPERMETABOLISM; MALE; NERVE DEGENERATION; NEUROIMAGING; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRECUNEUS; PRIORITY JOURNAL; TEMPORAL LOBE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; AMYLOID; ANILINE COMPOUNDS; APOLIPOPROTEIN E4; CEREBRAL CORTEX; CROSS-SECTIONAL STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THIAZOLES;

EID: 84903936942     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000467     Document Type: Article

References (40)

1. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367: 795-804.
2. Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013;12: 207-216.
3. Jack CR Jr, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009;132: 1355-1365.
4. Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013;12: 357-367.
5. Roberts RO, Geda YE, Knopman DS, et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 2008;30: 58-69.
6. 18F-FDG and PiB PET in cognitive impairment. J Nucl Med 2009;50: 878-886.
7. Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer; 2001.
8. Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw 2010;33: 1-22.
9. Meng XL, Rosenthal R, Rubin DB. Comparing correlated correlation coefficients. Psychol Bull 1992;111: 172-175.
10. Raghunathan ET, Rosenthal R, Rubin DB. Comparing correlated but nonoverlapping correlations. Psychol Methods 1996;1: 178-183.
11. Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008;131: 665-680.
12. 18F]-Fluorodeoxyglucose (FDG) and positron emission tomography (PET) in aging and dementia: a decade of studies. Eur Neurol 1989;29(suppl 3): 16-24.
13. Herholz K. FDG PET and differential diagnosis of dementia. Alzheimer Dis Assoc Disord 1995;9: 6-16.
14. Higuchi M, Arai H, Nakagawa T, et al. Regional cerebral glucose utilization is modulated by the dosage of apolipoprotein E type 4 allele and alpha1-Antichymotrypsin type A allele in Alzheimer's disease. Neuroreport 1997;8: 2639-2643.
15. Frey KA, Minoshima S, Kuhl DE. Neurochemical imaging of Alzheimer's disease and other degenerative dementias. Q J Nucl Med 1998;42: 166-178.
16. Hoffman JM, Welsh-Bohmer KA, Hanson M, et al. FDG PET imaging in patients with pathologically verified dementia. J Nucl Med 2000;41: 1920-1928.
17. De Leon MJ, Convit A, Wolf OT, et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F] fluoro-2-deoxy-D-glucose/positron- emission tomography (FDG/PET). Proc Natl Acad Sci USA 2001;98: 10966-10971.
18. Jagust WJ, Landau SM. Apolipoprotein E, not fibrillar beta-Amyloid, reduces cerebral glucose metabolism in normal aging. J Neurosci 2012;32: 18227-18233.
19. Cohen AD, Price JC, Weissfeld LA, et al. Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve. J Neurosci 2009;29: 14770-14778.
20. Oh H, Habeck C, Madison C, Jagust W. Covarying alterations in Abeta deposition, glucose metabolism, and gray matter volume in cognitively normal elderly. Hum Brain Mapp 2014;35: 297-308.
21. Mosconi L, Mistur R, Switalski R, et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging 2009;36: 811-822.
22. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl JMed 1996;334: 752-758.
23. Reiman EM, Chen K, Alexander GE, et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci USA 2004;101: 284-289.
24. Jack CR Jr, Knopman DS, Weigand SD, et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 2012;71: 765-775.
25. Kantarci K, Lowe VJ, Boeve BF, et al. Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging 2012;33: 2091-2105.
26. Rodrigue KM, Kennedy KM, Devous MD Sr, et al. Betaamyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology 2012;78: 387-395.
27. Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 2009; 106: 6820-6825.
28. Anandatheerthavarada HK, Biswas G, Robin MA, Avadhani NG. Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells. J Cell Biol 2003;161: 41-54.
29. Lim YA, Rhein V, Baysang G, et al. Abeta and human amylin share a common toxicity pathway via mitochondrial dysfunction. Proteomics 2010;10: 1621-1633.
30. Chang S, ran Ma T, Miranda RD, Balestra ME, Mahley RW, Huang Y. Lipid-And receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. Proc Natl Acad Sci USA 2005;102: 18694-18699.
31. Valla J, Yaari R, Wolf AB, et al. Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE epsilon4 allele, the major late-onset Alzheimer's susceptibility gene. J Alzheimers Dis 2010; 22: 307-313.
32. Zhong N, Ramaswamy G, Weisgraber KH. Apolipoprotein E4 domain interaction induces endoplasmic reticulum stress and impairs astrocyte function. J Biol Chem 2009; 284: 27273-27280.
33. Ma T, Du X, Pick JE, Sui G, Brownlee M, Klann E. Glucagon-like peptide-1 cleavage product GLP-1(9-36) amide rescues synaptic plasticity and memory deficits in Alzheimer's disease model mice. J Neurosci 2012;32: 13701-13708.
34. Langbaum JB, Chen K, Launer LJ, et al. Blood pressure is associated with higher brain amyloid burden and lower glucose metabolism in healthy late middle-Age persons. Neurobiol Aging 2012;33: 827.e11-827.e19.
35. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9: 119-128.
36. Forster S, Yousefi BH, Wester HJ, et al. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease. Eur J Nucl Med Mol Imaging 2012;39: 1927-1936.
37. Jack CR Jr, Wiste HJ, Lesnick TG, et al. Brain betaamyloid load approaches a plateau. Neurology 2013;80: 890-896.
38. Knopman DS, Jack CR Jr, Wiste HJ, et al. Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with b-Amyloidosis. JAMA Neurol 2013;70: 1030-1038.
39. Engler H, Forsberg A, Almkvist O, et al. Two-year followup of amyloid deposition in patients with Alzheimer's disease. Brain 2006;129: 2856-2866.
40. Cohen SI, Linse S, Luheshi LM, et al. Proliferation of amyloid-beta42 aggregates occurs through a secondary nucleation mechanism. Proc Natl Acad Sci USA 2013; 110: 9758-9763.